CN103608039A - 基于bcma的针对多发性骨髓瘤患者的分层与治疗 - Google Patents

基于bcma的针对多发性骨髓瘤患者的分层与治疗 Download PDF

Info

Publication number
CN103608039A
CN103608039A CN201280029972.2A CN201280029972A CN103608039A CN 103608039 A CN103608039 A CN 103608039A CN 201280029972 A CN201280029972 A CN 201280029972A CN 103608039 A CN103608039 A CN 103608039A
Authority
CN
China
Prior art keywords
bcma
cell
cells
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280029972.2A
Other languages
English (en)
Chinese (zh)
Inventor
E.伯格斯
J.B.赫比斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103608039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN103608039A publication Critical patent/CN103608039A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280029972.2A 2011-04-21 2012-04-20 基于bcma的针对多发性骨髓瘤患者的分层与治疗 Pending CN103608039A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11163558.7 2011-04-21
EP11163558 2011-04-21
PCT/EP2012/057248 WO2012143498A1 (en) 2011-04-21 2012-04-20 Bcma-based stratification and therapy for multiple myeloma patients

Publications (1)

Publication Number Publication Date
CN103608039A true CN103608039A (zh) 2014-02-26

Family

ID=44343806

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280029972.2A Pending CN103608039A (zh) 2011-04-21 2012-04-20 基于bcma的针对多发性骨髓瘤患者的分层与治疗

Country Status (19)

Country Link
US (3) US20130101599A1 (enExample)
EP (1) EP2699259B1 (enExample)
JP (1) JP2014520248A (enExample)
KR (1) KR20140031905A (enExample)
CN (1) CN103608039A (enExample)
AP (1) AP2013007178A0 (enExample)
AU (1) AU2012244676A1 (enExample)
CA (1) CA2832510A1 (enExample)
CL (1) CL2013003031A1 (enExample)
CO (1) CO6801644A2 (enExample)
EA (1) EA201301180A1 (enExample)
IL (1) IL228701A0 (enExample)
MA (1) MA35056B1 (enExample)
MX (1) MX2013012167A (enExample)
PE (1) PE20140612A1 (enExample)
PH (1) PH12013502147A1 (enExample)
SG (1) SG194500A1 (enExample)
TN (1) TN2013000412A1 (enExample)
WO (1) WO2012143498A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167964A (zh) * 2016-11-02 2019-08-23 英格玛布有限责任公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110431151A (zh) * 2016-12-21 2019-11-08 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN110891971A (zh) * 2017-06-20 2020-03-17 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN112698037A (zh) * 2021-03-25 2021-04-23 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN112955748A (zh) * 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889764C (en) * 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
JP2016507066A (ja) * 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
MX379210B (es) 2014-02-07 2025-03-10 Univ Mcmaster Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
IL303667A (en) * 2014-04-30 2023-08-01 Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft Humanized antibodies against cd269 (bcma)
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
ES2966099T3 (es) 2014-12-05 2024-04-18 Memorial Sloan Kettering Cancer Center Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
HUE053995T2 (hu) 2014-12-05 2021-08-30 Memorial Sloan Kettering Cancer Center B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
CN108350073B (zh) 2015-08-03 2022-03-18 英格玛布有限责任公司 针对bcma的单克隆抗体
PT3337824T (pt) 2015-08-17 2020-09-10 Janssen Pharmaceutica Nv Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
WO2017072716A1 (en) * 2015-10-30 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Prognostic method
JP7011600B2 (ja) 2016-01-12 2022-01-26 ジェイムズ リチャード ベレンソン， 被験体の免疫状態をモニタリングするための改善された方法
HK1259075A1 (zh) 2016-02-17 2019-11-22 Seattle Genetics, Inc. Bcma抗体和其用以治疗癌症和免疫病症的用途
KR20190053835A (ko) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 Cd3 결합 항체
CN114395048B (zh) 2016-09-14 2025-01-28 特纳奥尼股份有限公司 Cd3结合抗体
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
WO2018231949A1 (en) 2017-06-14 2018-12-20 Dana-Farber Cancer Institute, Inc. B-cell maturation antigen (bcma)-directed nanoparticles
CA3065951A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7137619B2 (ja) * 2017-09-29 2022-09-14 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
AU2018369883A1 (en) 2017-11-15 2020-05-28 Novartis Ag BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JOP20200292A1 (ar) 2018-05-16 2020-11-15 Stichting Vumc Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
WO2020047452A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
MX2021012205A (es) 2019-04-05 2022-02-21 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma.
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2021173995A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
MX2022014166A (es) 2020-05-11 2022-12-02 Janssen Biotech Inc Metodos para tratar el mieloma multiple.
WO2021234560A1 (en) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
CA3189297A1 (en) 2020-06-30 2022-01-06 Nathan Trinklein Multi-specific antibodies binding to bcma
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
US12016923B2 (en) 2021-06-01 2024-06-25 Triumvira Immunologics Usa, Inc. Claudin 18.2 T cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2024025967A1 (en) * 2022-07-28 2024-02-01 Springworks Therapeutics, Inc. Determination of bcma level on plasma cells by flow cytometry
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
SI2406284T1 (sl) * 2009-03-10 2017-01-31 Biogen Ma Inc. Anti-bcma protitelesa
EP2419446A4 (en) 2009-04-17 2013-01-23 Lpath Inc HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.J.NOVAK ET AL.: "Expression of BCMA,TACI,and BAFF-R in multiple myeloma:a mechanism for growth and survival", 《BLOOD》 *
JM BERGUA ET AL.: "Rituximab in CD20 positive multiple myeloma", 《LEUKEMIA》 *
MAUREEN C. RYAN ET AL.: "Antibody targeting of B-cell maturation antigen on malignant plasma cells", 《MOLECULAR CANCER THERAPEUTICS》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
CN110167964A (zh) * 2016-11-02 2019-08-23 英格玛布有限责任公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110167964B (zh) * 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110431151A (zh) * 2016-12-21 2019-11-08 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN110431151B (zh) * 2016-12-21 2023-07-18 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
US12371505B2 (en) 2016-12-21 2025-07-29 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
CN110891971A (zh) * 2017-06-20 2020-03-17 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN111094353A (zh) * 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CN112955748A (zh) * 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
CN112698037A (zh) * 2021-03-25 2021-04-23 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用

Also Published As

Publication number Publication date
EA201301180A1 (ru) 2014-03-31
US20140193433A1 (en) 2014-07-10
IL228701A0 (en) 2013-12-31
EP2699259B1 (en) 2016-07-27
CL2013003031A1 (es) 2014-08-18
WO2012143498A1 (en) 2012-10-26
MX2013012167A (es) 2013-12-10
AP2013007178A0 (en) 2013-10-31
PE20140612A1 (es) 2014-06-07
SG194500A1 (en) 2013-12-30
CO6801644A2 (es) 2013-11-29
US20160131655A1 (en) 2016-05-12
EP2699259A1 (en) 2014-02-26
KR20140031905A (ko) 2014-03-13
US20130101599A1 (en) 2013-04-25
CA2832510A1 (en) 2012-10-26
JP2014520248A (ja) 2014-08-21
PH12013502147A1 (en) 2014-01-13
TN2013000412A1 (en) 2015-03-30
MA35056B1 (fr) 2014-04-03
AU2012244676A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
EP2699259B1 (en) Bcma-based stratification and therapy for multiple myeloma patients
Sarantopoulos et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
JP7312706B2 (ja) 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ
US20220169694A1 (en) Chimeric antigen receptor t cell therapy
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
US10736963B2 (en) Methods for detecting tissue infiltrating NK cells
KR20190015408A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
JP2022532519A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
JP2024511373A (ja) がんのためのバイオマーカーおよびその使用
JP2017120263A (ja) 腫瘍由来の微小胞マーカーによる薬物感受性予測方法
HK1190937A (en) Bcma-based stratification and therapy for multiple myeloma patients
OA16773A (en) BCMA-based stratification and therapy for multiple myeloma patients.
WO2025077869A1 (en) Anti-ny-eso-1 antibodies and uses thereof
CN117510636A (zh) Gprc5d抗体及其应用
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190937

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140226

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1190937

Country of ref document: HK